vs
ARTIVION, INC.（AORT）とiRhythm Holdings, Inc.（IRTC）の財務データ比較。上の社名をクリックして会社を切り替えられます
iRhythm Holdings, Inc.の直近四半期売上が大きい（$208.9M vs $116.0M、ARTIVION, INC.の約1.8倍）。iRhythm Holdings, Inc.の純利益率が高く（2.7% vs 2.1%、差は0.6%）。iRhythm Holdings, Inc.の前年同期比売上増加率が高い（27.1% vs 19.2%）。iRhythm Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$14.5M vs $-7.9M）。過去8四半期でiRhythm Holdings, Inc.の売上複合成長率が高い（25.8% vs 9.1%）
Artivion, Inc.は心血管移植向けの極低温保存した人体組織の流通、及び医療機器の開発を行う医療企業です。同社の製品には、余分な細胞物質と抗原を除去する処理を施した人間の心臓弁、手術用接着剤BioGlueなどがあり、臨床現場のニーズに応えています。
iRhythm Holdingsは心臓ケア分野に特化したデジタルヘルスケア企業で、ウェアラブル型の携帯用心拍モニタリングデバイスとAI搭載の解析ツールを開発・販売しています。主に米国の医療機関と患者を対象に、心房細動などの不整脈の検出を支援し、臨床診断に有用なデータを提供しています。
AORT vs IRTC — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $116.0M | $208.9M |
| 純利益 | $2.4M | $5.6M |
| 粗利率 | 63.1% | 70.9% |
| 営業利益率 | 9.2% | 1.1% |
| 純利益率 | 2.1% | 2.7% |
| 売上前年比 | 19.2% | 27.1% |
| 純利益前年比 | 114.7% | 518.5% |
| EPS（希薄化後） | $0.06 | $0.18 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $116.0M | $208.9M | ||
| Q3 25 | $113.4M | $192.9M | ||
| Q2 25 | $113.0M | $186.7M | ||
| Q1 25 | $99.0M | $158.7M | ||
| Q4 24 | $97.3M | $164.3M | ||
| Q3 24 | $95.8M | $147.5M | ||
| Q2 24 | $98.0M | $148.0M | ||
| Q1 24 | $97.4M | $131.9M |
| Q4 25 | $2.4M | $5.6M | ||
| Q3 25 | $6.5M | $-5.2M | ||
| Q2 25 | $1.3M | $-14.2M | ||
| Q1 25 | $-505.0K | $-30.7M | ||
| Q4 24 | $-16.5M | $-1.3M | ||
| Q3 24 | $-2.3M | $-46.2M | ||
| Q2 24 | $-2.1M | $-20.1M | ||
| Q1 24 | $7.5M | $-45.7M |
| Q4 25 | 63.1% | 70.9% | ||
| Q3 25 | 65.6% | 71.1% | ||
| Q2 25 | 64.7% | 71.2% | ||
| Q1 25 | 64.2% | 68.8% | ||
| Q4 24 | 63.2% | 70.0% | ||
| Q3 24 | 63.7% | 68.8% | ||
| Q2 24 | 64.6% | 69.9% | ||
| Q1 24 | 64.6% | 66.3% |
| Q4 25 | 9.2% | 1.1% | ||
| Q3 25 | 11.1% | -4.4% | ||
| Q2 25 | 7.4% | -10.0% | ||
| Q1 25 | 2.2% | -20.5% | ||
| Q4 24 | 2.7% | -2.5% | ||
| Q3 24 | 4.6% | -34.1% | ||
| Q2 24 | 6.6% | -15.5% | ||
| Q1 24 | 26.0% | -28.9% |
| Q4 25 | 2.1% | 2.7% | ||
| Q3 25 | 5.7% | -2.7% | ||
| Q2 25 | 1.2% | -7.6% | ||
| Q1 25 | -0.5% | -19.3% | ||
| Q4 24 | -16.9% | -0.8% | ||
| Q3 24 | -2.4% | -31.3% | ||
| Q2 24 | -2.2% | -13.6% | ||
| Q1 24 | 7.7% | -34.6% |
| Q4 25 | $0.06 | $0.18 | ||
| Q3 25 | $0.13 | $-0.16 | ||
| Q2 25 | $0.03 | $-0.44 | ||
| Q1 25 | $-0.01 | $-0.97 | ||
| Q4 24 | $-0.40 | $-0.03 | ||
| Q3 24 | $-0.05 | $-1.48 | ||
| Q2 24 | $-0.05 | $-0.65 | ||
| Q1 24 | $0.18 | $-1.47 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $64.9M | $583.8M |
| 総負債低いほど良い | $215.1M | — |
| 株主資本純資産 | $448.2M | $152.7M |
| 総資産 | $884.8M | $1.0B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $64.9M | $583.8M | ||
| Q3 25 | $73.4M | $565.2M | ||
| Q2 25 | $53.5M | $545.5M | ||
| Q1 25 | $37.7M | $520.6M | ||
| Q4 24 | $53.5M | $535.6M | ||
| Q3 24 | $56.2M | $522.0M | ||
| Q2 24 | $55.0M | $561.5M | ||
| Q1 24 | $51.1M | $569.1M |
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
| Q4 25 | $448.2M | $152.7M | ||
| Q3 25 | $438.7M | $121.9M | ||
| Q2 25 | $419.9M | $103.7M | ||
| Q1 25 | $294.3M | $86.7M | ||
| Q4 24 | $276.2M | $90.9M | ||
| Q3 24 | $304.7M | $71.8M | ||
| Q2 24 | $295.1M | $99.2M | ||
| Q1 24 | $295.0M | $90.3M |
| Q4 25 | $884.8M | $1.0B | ||
| Q3 25 | $857.7M | $995.2M | ||
| Q2 25 | $838.4M | $964.0M | ||
| Q1 25 | $791.2M | $926.1M | ||
| Q4 24 | $789.1M | $931.4M | ||
| Q3 24 | $803.1M | $909.7M | ||
| Q2 24 | $789.5M | $919.2M | ||
| Q1 24 | $784.0M | $909.8M |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.6M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $-7.9M | $14.5M |
| FCFマージンFCF / 売上 | -6.9% | 6.9% |
| 設備投資強度設備投資 / 売上 | 23.7% | 5.6% |
| キャッシュ転換率営業CF / 純利益 | 8.06× | 4.70× |
| 直近12ヶ月FCF直近4四半期 | $839.0K | $34.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.6M | $26.2M | ||
| Q3 25 | $22.3M | $34.9M | ||
| Q2 25 | $15.0M | $27.7M | ||
| Q1 25 | $-17.0M | $-7.9M | ||
| Q4 24 | $10.1M | $19.2M | ||
| Q3 24 | $11.5M | $24.3M | ||
| Q2 24 | $6.1M | $11.8M | ||
| Q1 24 | $-5.5M | $-52.0M |
| Q4 25 | $-7.9M | $14.5M | ||
| Q3 25 | $17.7M | $20.1M | ||
| Q2 25 | $11.7M | $17.3M | ||
| Q1 25 | $-20.6M | $-17.3M | ||
| Q4 24 | $8.7M | $12.4M | ||
| Q3 24 | $7.8M | $15.5M | ||
| Q2 24 | $3.6M | $3.4M | ||
| Q1 24 | $-9.1M | $-61.8M |
| Q4 25 | -6.9% | 6.9% | ||
| Q3 25 | 15.6% | 10.4% | ||
| Q2 25 | 10.4% | 9.3% | ||
| Q1 25 | -20.8% | -10.9% | ||
| Q4 24 | 9.0% | 7.5% | ||
| Q3 24 | 8.2% | 10.5% | ||
| Q2 24 | 3.7% | 2.3% | ||
| Q1 24 | -9.3% | -46.8% |
| Q4 25 | 23.7% | 5.6% | ||
| Q3 25 | 4.1% | 7.7% | ||
| Q2 25 | 2.9% | 5.6% | ||
| Q1 25 | 3.7% | 5.9% | ||
| Q4 24 | 1.5% | 4.2% | ||
| Q3 24 | 3.8% | 6.0% | ||
| Q2 24 | 2.6% | 5.7% | ||
| Q1 24 | 3.7% | 7.4% |
| Q4 25 | 8.06× | 4.70× | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
